Floatz logo

Retlirafusp Alfa

Non-Small Cell Lung Carcinoma

Fudan Universitymonoclonal_antibodyPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

1127 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Retlirafusp Alfa is also rated in:

colorectal cancerActive
B
Indicative · Phase 2/3
60 / 100
View asset →
castration-resistant prostate carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
cancerDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →